Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.
Journal: Blood cancer journal
Published: May 27, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Journal: American journal of hematology
Published: May 13, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.
Journal: American journal of hematology
Published: May 12, 2026
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.
Journal: American journal of hematology
Published: March 30, 2026
Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.
Journal: Blood
Published: March 13, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.
Journal: Blood cancer journal
Published: November 28, 2025
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.
Journal: American journal of hematology
Published: November 27, 2025
Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.
Journal: American journal of hematology
Published: October 23, 2025
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.
Journal: Leukemia & lymphoma
Published: October 10, 2025
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.
Journal: Haematologica
Published: September 25, 2025
Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.
Journal: Cancer medicine
Published: September 11, 2025
Last Updated: 09/26/2026